HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

This study is looking at whether combining three treatments — a targeted chemotherapy delivered directly into the liver (HAIC), a targeted drug called lenvatinib, and an immune checkpoint inhibitor (a PD-1 blocker) — works better than lenvatinib alone for a specific, aggressive form of liver cancer called infiltrative hepatocellular carcinoma. **You may be eligible if...** - You have been diagnosed with infiltrative liver cancer (HCC) confirmed by MRI or CT scan - You are between 18 and 75 years old - Your liver function is relatively preserved (Child-Pugh class A or B) - You have not received prior systemic therapy for this cancer - You have a good functional status (able to carry out daily activities with little limitation) **You may NOT be eligible if...** - Your liver cancer has a defined tumor capsule around it - You have had another cancer in the past - The cancer has spread into the heart chambers or major blood vessels - You have had sorafenib or other systemic treatments before Talk to your doctor to see if this trial is right for you.